GlassScriptPhysician profile
Carol D Vaughan
NPI 1902868896
$1,214.55
in general payments reported to CMS, 2019-2025
15 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $85.95 · 2022: $21.70 · 2023: $365 · 2024: $364 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $341.41 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $278.44 | 2023-2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $118.38 | 2023-2025 | |
| Lilly USA, LLC | $108.23 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $67.73 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $50.57 | 2023-2025 | Bexsero, Arexvy, Shingrix |
| Abbvie INC. | $47.86 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $43.73 | 2024 | Airsupra, Breztri |
| Dexcom, INC. | $33.28 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $31.36 | 2021 | |
| Pfizer INC. | $21.64 | 2023 | |
| Abbott Laboratories | $21.33 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $20.73 | 2024 | Repatha |
| Biotronik Nro, INC. | $15.50 | 2024 | Prospera |
| Kowa Pharmaceuticals America, INC. | $14.36 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Vaughan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.